GlassScriptPhysician profile
Craig S Sauter
NPI 1447494612
$51,027.32
in general payments reported to CMS, 2019-2025
21 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $11K · 2021: $640 · 2022: $8,858 · 2023: $7,202 · 2024: $467 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,350 · Consulting Fee: $1,950 · Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,350.00 |
| Consulting Fee | $1,950.00 |
| Food and Beverage | $1,661.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $17,098.17 | 2019-2023 | Yescarta |
| Celgene Corporation | $8,057.13 | 2019 | |
| Glaxosmithkline, LLC. | $6,375.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $4,739.01 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $4,350.00 | 2023 | Tazverik |
| Morphosys, US INC. | $2,767.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $2,139.90 | 2023 | Abecma |
| Gilead Sciences, INC. | $2,060.00 | 2022 | |
| Karyopharm Therapeutics INC. | $1,937.50 | 2020 | |
| Adc Therapeutics America, INC. | $375.46 | 2023-2025 | |
| Genmab U.S., INC. | $352.61 | 2023-2025 | Epkinly |
| Biolinerx USA, INC. | $264.08 | 2024 | Aphexda |
| Seagen INC. | $172.00 | 2023 | |
| National Marrow Donor Program | $156.36 | 2022 | |
| Rigel Pharmaceuticals, INC. | $52.99 | 2024 | Tavalisse, Rezlidhia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45.68 | 2023 | |
| Stemline Therapeutics INC. | $35.07 | 2024 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $26.44 | 2022 | |
| Medline Industries LP | $21.53 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Sauter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.